3 active not recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 3 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow NF1: new trials by email Literature Review of NF1 trials Research Report on NF1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 FCN-159 - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 160 | 2021-03-26 | 2024-11-12 |
| Interventions for Reading Disabilities in NF1 Lovastatin, reading tutoring intervention, Placebo Oral Tablet - Neurofibromatosis Type 1, Learning Disability | Phase 2 | Active not recruiting | Vanderbilt University | 120 | 2016-11-01 | 2026-07-01 |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors AZD6244 - Neurofibromatosis 1, Neurofibromatosis Type 1 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 99 | 2011-09-21 | 2026-10-27 |
Neurofibromatosis 1 (3) · Neurofibroma, Plexiform (2) · Dyslexia (1) · Learning Disabilities (1) · Pain (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Heredodegenerative Disorders, Nervous System (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Nerve Tissue (3) · Neoplastic Syndromes, Hereditary (3) · Nerve Sheath Neoplasms (3) · Nervous System Diseases (3) · Neurocutaneous Syndromes (3) · Neurodegenerative Diseases (3) · Neurofibroma (3) · Neurofibromatoses (3) · Neuromuscular Diseases (3) · Peripheral Nervous System Diseases (3)
AZD 6244 (1) · Lovastatin (1)
National Cancer Institute (NCI) (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · Vanderbilt University (1)
United States (3) · China (1) · Spain (1)
Brigitte C Widemann, M.D. (1) · Laurie Cutting, PhD (1) · Sheryl L. Rimrodt-Frierson, MD (1)
PMID 28029918, PMID 32187457, PMID 35467749, PMID 37115514, PMID 37400844, PMID 38869947, PMID 40709016, PMID 41139346, PMID 42540436
R01HD089474 (1)